{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T21:42:33Z","timestamp":1758663753349,"version":"3.44.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clon.2025.103899","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:53:15Z","timestamp":1751424795000},"page":"103899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real World Multi-centre UK Review of Nivolumab Monotherapy in Metastatic Endometrial Cancer With Mismatch Repair Deficiency During COVID-19"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9371-3250","authenticated-orcid":false,"given":"J.","family":"McGrane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Eastlake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1147-3618","authenticated-orcid":false,"given":"D.","family":"Hadjiyiannakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1169-6125","authenticated-orcid":false,"given":"S.","family":"Lalondrelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1602-1124","authenticated-orcid":false,"given":"S.","family":"Trent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Obeid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5730-4468","authenticated-orcid":false,"given":"E.","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1946-7412","authenticated-orcid":false,"given":"R.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4085-4362","authenticated-orcid":false,"given":"T.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kristeleit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8993-0148","authenticated-orcid":false,"given":"M.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4141-822X","authenticated-orcid":false,"given":"J.","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6148-0077","authenticated-orcid":false,"given":"L.","family":"Seneviratne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.J.","family":"Melendez-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clon.2025.103899_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.clon.2025.103899_bib2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.5114\/aoms.2010.19305","article-title":"Long-term survival of endometrioid endometrial cancer patients","volume":"6","author":"Gottwald","year":"2010","journal-title":"Arch Med Sci"},{"issue":"4","key":"10.1016\/j.clon.2025.103899_bib3","first-page":"221","article-title":"Age-period-cohort analyses of breast-, ovarian-, endometrial- and cervical-cancer mortality rates for Caucasian women in the USA","volume":"5","author":"Tarone","year":"2000","journal-title":"J Epidemiol Biostat"},{"issue":"3","key":"10.1016\/j.clon.2025.103899_bib4","first-page":"179","article-title":"Factors predicting recurrent endometrial cancer","volume":"5","author":"Huijgens","year":"2013","journal-title":"Facts Views Vis Obgyn"},{"issue":"33","key":"10.1016\/j.clon.2025.103899_bib5","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clon.2025.103899_bib6","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative","volume":"28","author":"Stelloo","year":"2015","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.clon.2025.103899_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/ijgc-2022-004039","article-title":"Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program","volume":"33","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"23","key":"10.1016\/j.clon.2025.103899_bib8","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"RUBY Investigators. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.clon.2025.103899_bib9","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clon.2025.103899_bib10","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1158\/1078-0432.CCR-22-3915","article-title":"Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study","volume":"29","author":"Oaknin","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.clon.2025.103899_bib11","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"RUBY Investigators. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"S2","key":"10.1016\/j.clon.2025.103899_bib12","article-title":"LBA40 Phase III double-blind randomized placebo-controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced\/recurrent endometrial carcinoma","volume":"34","author":"Colombo","year":"2023","journal-title":"Ann Onc"},{"issue":"6","key":"10.1016\/j.clon.2025.103899_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002255","article-title":"Australia New Zealand Gynaecological Oncology Group (ANZGOG). Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial","volume":"9","author":"Antill","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"23","key":"10.1016\/j.clon.2025.103899_bib14","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2025.103899_bib15","unstructured":"COVID-19 rapid guideline: delivery of systemic anticancer treatments. NICE guideline: NG161 https:\/\/www.nice.org.uk\/guidance\/ng161\/resources\/interim-treatment-change-options-during-the-covid19-pandemic-endorsed-by-nhs-england-pdf-8715724381."},{"issue":"1","key":"10.1016\/j.clon.2025.103899_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Non-colorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clon.2025.103899_bib17","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1111\/cas.14148","article-title":"Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial","volume":"110","author":"Tamura","year":"2019","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.clon.2025.103899_bib18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"DUO-E Investigators. Durvalumab Plus Carboplatin\/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial","volume":"42","author":"Westin","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2025.103899_bib19","unstructured":"Colombo N, Biagioli E, Haran K, Galli F, Hudson E, Antill Y et al. Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncol, Volume 25, Issue 9, 1135 \u2013 1146."},{"issue":"16","key":"10.1016\/j.clon.2025.103899_bib20","article-title":"Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced\/metastatic setting: DOMENICA study (GINECO-EN105b\/ENGOT-en13 study)","volume":"41","author":"Joly","year":"2023","journal-title":"J Clin Onc"},{"key":"10.1016\/j.clon.2025.103899_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103539","article-title":"Phase III ENGOT-En9\/LEAP-001 study: Lenvatinib + pembrolizumab (LEN\/PEMBRO) vs chemotherapy (chemo) as first-line (1L) therapy for advanced or recurrent endometrial cancer","volume":"9","author":"Pignata","year":"2024","journal-title":"ESMO Open"},{"issue":"Supplement 1","key":"10.1016\/j.clon.2025.103899_bib22","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.ygyno.2024.07.094","article-title":"Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: Primary results of the phase 3 ENGOT-en9\/LEAP-001 study. Society of Gynecologic Oncology 2024 Annual Meeting","volume":"190","author":"Marth","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.clon.2025.103899_bib23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Study 309\u2013KEYNOTE-775 Investigators. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.clon.2025.103899_bib24","doi-asserted-by":"crossref","first-page":"p2904","DOI":"10.1200\/JCO.22.02152","article-title":"Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: Updated efficacy and safety from the randomised Phase III study 309\/KEYNOTE-775","volume":"41","author":"Makker","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655525001542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655525001542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T21:20:25Z","timestamp":1758662425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655525001542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":24,"alternative-id":["S0936655525001542"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2025.103899","relation":{},"ISSN":["0936-6555"],"issn-type":[{"type":"print","value":"0936-6555"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real World Multi-centre UK Review of Nivolumab Monotherapy in Metastatic Endometrial Cancer With Mismatch Repair Deficiency During COVID-19","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2025.103899","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103899"}}